Quiz
TBI and Schizophrenia Risk
FDA Alerts
10/09/2026
Brionna Mendoza
Teva Pharmaceuticals announced the FDA approval of subcutaneous olanzapine (Weltruza) for extended-release injectable suspension on October 9, 2026.
Teva Pharmaceuticals announced the FDA approval of subcutaneous olanzapine (Weltruza) for extended-release injectable suspension on October 9, 2026.
Teva Pharmaceuticals announced...
10/09/2026
Psych Congress Network
FDA Alerts
10/08/2026
Maria Mantas
The US Food and Drug Administration (FDA) granted 510(k) clearance for Motivista, the first treatment specifically authorized for negative symptoms of schizophrenia in adults.
The US Food and Drug Administration (FDA) granted 510(k) clearance for Motivista, the first treatment specifically authorized for negative symptoms of schizophrenia in adults.
The US Food and Drug...
10/08/2026
Psych Congress Network
Research Summary
10/06/2026
Brionna Mendoza
Young people beginning antipsychotic treatment after first-episode psychosis had low medication adherence, according to a retrospective US cohort study published in JAMA Network Open.
Young people beginning antipsychotic treatment after first-episode psychosis had low medication adherence, according to a retrospective US cohort study published in JAMA Network Open.
Young people beginning...
10/06/2026
Psych Congress Network
News
07/01/2026
Maria Mantas
Sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with a lower risk of incident all-cause dementia among older US veterans with mood and psychotic disorders.
Sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with a lower risk of incident all-cause dementia among older US veterans with mood and psychotic disorders.
Sodium-glucose cotransporter 2...
07/01/2026
Psych Congress Network
